<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02378064</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2014-10</org_study_id>
    <nct_id>NCT02378064</nct_id>
  </id_info>
  <brief_title>Comparison of Fimasartan Versus Amlodipine Therapy on Carotid PlaquE Inflammation</brief_title>
  <acronym>FACE</acronym>
  <official_title>Comparison of Fimasartan Versus Amlodipine Therapy on Carotid PlaquE Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHEOL WHAN LEE, M.D., Ph.D</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of angiotensin receptor 1 blocker versus
      calcium channel blocker on atherosclerotic plaque inflammation using serial FDG PET/CT
      imaging of carotid artery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change (follow-up minus baseline) in standardized FDG uptake value</measure>
    <time_frame>6month</time_frame>
    <description>change (follow-up minus baseline) in standardized FDG uptake value within the regions of interest, known as a target-to-background ratio (blood-normalized standardized uptake value).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes of blood pressure</measure>
    <time_frame>6month</time_frame>
    <description>systolic and diastolic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial changes of lipid battery</measure>
    <time_frame>6month</time_frame>
    <description>total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Inflammation Plaque, Atherosclerotic</condition>
  <condition>Coronary Disease</condition>
  <condition>Renin-Angiotensin System</condition>
  <arm_group>
    <arm_group_label>Fimasartan and vytorin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fimasartan(60mg,QD)+Vytorin(10mg,QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan and rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fimasartan(60mg,QD)+rosuvastatin(5mg,QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amlodipine and vytorin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amlodipine(5mg,QD)+Vytorin(10mg,QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amlodipine and rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amlodipine(5mg,QD+rosuvastatin(5mg,QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-month treatment</intervention_name>
    <arm_group_label>Fimasartan and vytorin</arm_group_label>
    <arm_group_label>Fimasartan and rosuvastatin</arm_group_label>
    <arm_group_label>amlodipine and vytorin</arm_group_label>
    <arm_group_label>amlodipine and rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or Women at least 18 years of age inclusive

          -  Patients with acute coronary syndromes or unstable angina pectoris

          -  Hypertension or blood pressure more than 140/90mmHg

          -  FDG PET/CT shows at least 1 hot uptakes at carotid and or ascending aorta

          -  The patient or guardian agrees to the study protocol and the schedule of clinical and
             FDG PET/CT follow-up, and provides informed, written consent, as approved by the
             appropriate Institutional Review Board/Ethical Committee of the respective clinical
             site.

        Exclusion Criteria:

          -  Patients treated with carotid endarterectomy or stent placement

          -  Chronic disease requiring treatment with oral, intravenous, or intra-articular
             corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible).

          -  Untreated hyperthyroidism, or hypothyroidism

          -  Any clinically significant abnormality identified at the screening visit, physical
             examination, laboratory tests, or electrocardiogram which, in the judgment of the
             Investigator, would preclude safe completion of the study.

          -  Evidence of congestive heart failure, or left ventricular ejection fraction &lt; 40%.

          -  Significant renal disease manifested by serum creatinine &gt; 2.0mg/dL, or creatinine
             clearance of &lt; 40 ml/min (by Cockcroft-Gault method).

          -  Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation
             (ALT or AST &gt; 3 times upper limit of normal).

          -  History of adult asthma manifested by bronchospasm in the past 6 months, or currently
             taking regular anti-asthmatic medication(s).

          -  Unwillingness or inability to comply with the procedures described in this protocol.

          -  Patient's pregnant or breast-feeding or child-bearing potential.

          -  Type I Diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>February 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>CHEOL WHAN LEE, M.D., Ph.D</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Fluorodeoxyglucose F18</keyword>
  <keyword>Positron-Emission Tomography and Computed Tomography</keyword>
  <keyword>Plaque, Atherosclerotic</keyword>
  <keyword>Renin-Angiotensin System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

